Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
出版年份 2015 全文链接
标题
Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
作者
关键词
-
出版物
BRITISH JOURNAL OF CANCER
Volume 112, Issue 12, Pages 1888-1894
出版商
Springer Nature
发表日期
2015-05-20
DOI
10.1038/bjc.2015.173
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis
- (2015) Filippo Pietrantonio et al. EUROPEAN JOURNAL OF CANCER
- The predictive value ofKRAS, NRAS, BRAF, PIK3CAand PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis
- (2014) Christina Therkildsen et al. ACTA ONCOLOGICA
- ExtendedRASmutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials
- (2014) M. J. Sorich et al. ANNALS OF ONCOLOGY
- American Society of Clinical Oncology Position Statement on Obesity and Cancer
- (2014) Jennifer A. Ligibel et al. JOURNAL OF CLINICAL ONCOLOGY
- Patient and Tumor Characteristics and BRAF and KRAS Mutations in Colon Cancer, NCCTG/Alliance N0147
- (2014) Wilson I. Gonsalves et al. JNCI-Journal of the National Cancer Institute
- Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer
- (2013) M. Peeters et al. CLINICAL CANCER RESEARCH
- PIK3CA, BRAF , and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17
- (2013) Christos S. Karapetis et al. CLINICAL CANCER RESEARCH
- Somatic Profiling of the Epidermal Growth Factor Receptor Pathway in Tumors from Patients with Advanced Colorectal Cancer Treated with Chemotherapy Cetuximab
- (2013) C. G. Smith et al. CLINICAL CANCER RESEARCH
- Promising biomarkers for predicting the outcomes of patients withKRASwild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: A systematic review with meta-analysis
- (2013) Zu-Yao Yang et al. INTERNATIONAL JOURNAL OF CANCER
- Predictive and prognostic roles ofBRAFmutation in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: A meta-analysis
- (2013) Qi Xu et al. Journal of Digestive Diseases
- Microsatellite Instability and BRAF Mutation Testing in Colorectal Cancer Prognostication
- (2013) Paul Lochhead et al. JNCI-Journal of the National Cancer Institute
- Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial
- (2013) Matthew T Seymour et al. LANCET ONCOLOGY
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Prognostic Role of BRAF Mutation in Metastatic Colorectal Cancer Receiving Anti-EGFR Monoclonal Antibodies: A Meta-Analysis
- (2013) Zi-Xu Yuan et al. PLoS One
- Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials
- (2012) Carsten Bokemeyer et al. EUROPEAN JOURNAL OF CANCER
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
- (2012) Anirudh Prahallad et al. NATURE
- The Prognostic Value of BRAF Mutation in Colorectal Cancer and Melanoma: A Systematic Review and Meta-Analysis
- (2012) Gholamreza Safaee Ardekani et al. PLoS One
- Prospective–retrospective biomarker analysis for regulatory consideration: white paper from the industry pharmacogenomics working group
- (2011) Scott D Patterson et al. PHARMACOGENOMICS
- Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal
- (2010) David M Kent et al. Trials
- Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant
- (2009) F Molinari et al. BRITISH JOURNAL OF CANCER
- KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
- (2009) F Loupakis et al. BRITISH JOURNAL OF CANCER
- Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer
- (2009) Pierre Laurent-Puig et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
- (2009) R. M. Simon et al. JNCI-Journal of the National Cancer Institute
- BRAFMutation in Metastatic Colorectal Cancer
- (2009) Jolien Tol et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer
- (2009) Andrea Sartore-Bianchi et al. PLoS One
- PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients
- (2008) F. Perrone et al. ANNALS OF ONCOLOGY
- Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients
- (2008) F Cappuzzo et al. BRITISH JOURNAL OF CANCER
- Association of K-ras Mutational Status and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Receiving Panitumumab Alone
- (2008) Daniel J. Freeman et al. Clinical Colorectal Cancer
- Wild-TypeBRAFIs Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
- (2008) Federica Di Nicolantonio et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started